Acasti Pharma Total Liabilities 2014-2024 | GRCE
Acasti Pharma total liabilities from 2014 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Acasti Pharma Annual Total Liabilities
(Millions of US $) |
| 2024 |
$12 |
| 2023 |
$11 |
| 2022 |
$20 |
| 2021 |
$7 |
| 2020 |
$10 |
| 2019 |
$26 |
| 2018 |
$11 |
| 2017 |
$3 |
| 2016 |
$1 |
| 2015 |
$1 |
| 2015 |
$ |
| 2014 |
$12 |
| 2014 |
$ |
| 2013 |
$2 |
| 2013 |
$ |
Acasti Pharma Quarterly Total Liabilities
(Millions of US $) |
| 2024-06-30 |
$10 |
| 2024-03-31 |
$12 |
| 2023-12-31 |
$12 |
| 2023-09-30 |
$11 |
| 2023-06-30 |
$9 |
| 2023-03-31 |
$11 |
| 2022-12-31 |
$20 |
| 2022-09-30 |
$21 |
| 2022-06-30 |
$21 |
| 2022-03-31 |
$20 |
| 2021-12-31 |
$3 |
| 2021-09-30 |
$6 |
| 2021-06-30 |
$7 |
| 2021-03-31 |
$7 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$5 |
| 2020-06-30 |
$9 |
| 2020-03-31 |
$10 |
| 2019-12-31 |
$34 |
| 2019-09-30 |
$30 |
| 2019-06-30 |
$26 |
| 2019-03-31 |
$26 |
| 2018-12-31 |
$22 |
| 2018-09-30 |
$27 |
| 2018-06-30 |
$15 |
| 2018-03-31 |
$11 |
| 2017-12-31 |
$9 |
| 2017-09-30 |
$4 |
| 2017-06-30 |
$3 |
| 2017-02-28 |
$3 |
| 2016-11-30 |
$1 |
| 2016-08-31 |
$1 |
| 2016-05-31 |
$1 |
| 2016-03-31 |
$1 |
| 2016-02-29 |
|
| 2015-12-31 |
$1 |
| 2015-09-30 |
$1 |
| 2015-06-30 |
$2 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$3 |
| 2014-09-30 |
$9 |
| 2014-06-30 |
$8 |
| 2014-03-31 |
$12 |
| 2014-02-28 |
|
| 2013-12-31 |
$5 |
| 2013-09-30 |
$4 |
| 2013-06-30 |
$3 |
| 2013-03-31 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
